Marrow-replenishing blood-nourishing pill

Abstract

The invention discloses a marrow-replenishing blood-nourishing pill having no toxic and side effect and low cost, which is invented for the purpose of solving the problems of high cost and the like in the prior art. The marrow-replenishing blood-nourishing pill is prepared from the following active pharmaceutical ingredients by weights: 100g of ginseng, 50g of astragalus root, 10g of cornu cervi pantotrichum, 20g of medical dogwood, 30g of prepared fleece flower root, 10g of prepared nux vomica, 10g of batryticated silkworm, 15g of notoginseng, 40g of bighead atractylodes rhizome, 40g of prepared rehmannia root, 30g of radix salviae miltiorrhizae, 30g of donkey-hide gelatin, 30g of venison, 50g of walnut kernel, 20g of dried ginger, 240g of fine wheat flour and 30g of white paeony root; the active pharmaceutical ingredients are crushed and then prepared into honeyed pills with a proper amount of honey. The marrow-replenishing blood-nourishing pill has the functions of invigorating qi, nourishing blood, regulating yin and yang, warming and invigorating kidney and stimulating hematopoiesis. In accordance with the clinical trial to 128 cases, the marrow-replenishing blood-nourishing pill has the total effective rate as high as 95% and the curative rate as high as 78%.

Description

technical field [0001] The invention relates to a traditional Chinese medicine, in particular to a traditional Chinese medicine for treating aplastic anemia-filling marrow Shengxue Dan. Background technique [0002] Aplastic anemia is referred to as aplastic anemia. It is a hematopoietic disorder caused by a variety of etiologies, resulting in a decrease in the total volume of red bone marrow, replaced by fatty marrow, hematopoietic failure, and a group of syndromes mainly manifested in pancytopenia. According to the survey of aplastic anemia (city) autonomous regions in 21 provinces in China, the annual incidence rate is 0.74 / 100,000 population, which is significantly lower than the incidence rate of leukemia; the incidence rate of chronic aplastic anemia is 0.60 / 100,000 population, and acute aplastic anemia is 0.14 / 100,000 population; it can occur in all age groups, but it is more common in young adults; the incidence rate of men is slightly higher than that of women. G...

AI Technical Summary

Problems solved by technology

[0003] The treatment of aplastic anemia is mainly based on androgen or bone marrow transplantation. The use of androgen plus other comprehensive treatments requires long-term unremitting efforts to achieve satisfactory curative effect, but its side effects are relatively large; bone marrow transplantation is the treatment of stem cell defects. The best method for aplastic anemia, but its cost is high, and the survival rate is only 60%-80%